MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas

Area of Science:

• Oncology
• Analytical Chemistry
• Biomarker Discovery

Background:

• Renal cell carcinoma (RCC) is a common cancer with a lack of established prognostic biomarkers.
• Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) shows promise for detecting cancer biomarkers.
• Identifying prognostic markers is crucial for improving RCC patient outcomes.

Purpose of the Study:

• To identify prognostic biomarkers for renal cell carcinoma (RCC) using MALDI-MSI.
• To analyze a large, multicenter cohort encompassing the three main RCC subtypes: clear cell RCC (ccRCC), papillary RCC (pRCC), and chromophobe RCC (chRCC).
• To correlate metabolic features with clinical outcomes, specifically overall survival.

Main Methods:

• High mass resolution MALDI-Fourier-transform ion cyclotron resonance (FT-ICR)-MSI was performed on renal carcinoma tissue sections from 782 patients.
• The SPACiAL pipeline was used for automated co-registration of histological and molecular data.
• Kaplan-Meier analyses were conducted to assess the association between metabolic features and overall survival.

Main Results:

• Several metabolic pathways and individual metabolites were identified with prognostic significance for RCC overall.
• Specific prognostic metabolic features were also detected for individual RCC subtypes (ccRCC, pRCC, chRCC).
• The study successfully linked molecular data from MSI with clinical outcome data.

Conclusions:

• MALDI-MSI is a powerful tool for discovering prognostic biomarkers in renal cell carcinoma.
• The identified metabolic features offer potential for improving RCC patient stratification and treatment strategies.
• This study provides valuable insights into the molecular heterogeneity of RCC and its impact on prognosis.